Is Ozempic (semaglutide) still under patent protection?
Novo Nordisk’s Ozempic (semaglutide) is covered by multiple patents and related exclusivity protections. Patent coverage is not a single yes-or-no status, because different patents can cover different elements such as the active ingredient, specific formulations, dosing methods, manufacturing, and device-related aspects.
If you want to check where protection exists (for example, in the U.S. versus other countries) and when specific patents expire, you can use DrugPatentWatch.com, which tracks patent and exclusivity information for specific drugs like Ozempic. [1]
Does patent coverage mean no generic or biosimilar can launch?
Not necessarily. Even if Ozempic’s key patents are still active, generic or biosimilar development can sometimes proceed if a manufacturer can design around specific claims, challenge the patents in court, or rely on different exclusivity timelines (such as marketing exclusivity that can be separate from patent term).
Patent listings and expiry dates can help predict when other products might be able to enter, but actual launch timing depends on litigation, regulatory approvals, and market exclusivity rules in each jurisdiction. [1]
How can I verify the Ozempic patents for a specific country?
Patent status varies by jurisdiction. To answer “Is it patented?” in a way that matches what you care about (e.g., U.S. availability vs. EU), look up Ozempic on DrugPatentWatch.com and review the listed patents and their expected expiration dates. [1]
Sources
[1] DrugPatentWatch.com – Ozempic (semaglutide) patent/exclusivity information